SCHEMBL6487467

SCHEMBL6487467

CCCCCCCCCCCCCCN1CCN(C(=O)OCc2ccccc2)CC1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.46
PLA2G2A P14555 2/20 0.46
PRCP P42785 1/20 0.46
TMEM97 Q5BJF2 9/20 0.46
SIGMAR1 Q99720 9/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
DRD1 P21728 1/20 0.45
HRH2 P25021 1/20 0.45
HTR1B P28222 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28431069 0.99 MEN1 (0.47) ELANEPLA2G2APRCPTMEM97SIGMAR1
SCHEMBL28429226 0.95 MEN1 (0.48) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL16475199 0.91 TMEM97 (0.52) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL3622805 0.84 MEN1 (0.51) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL28433633 0.84 P2RX7 (0.49) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL4391159 0.83 MEN1 (0.50) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL7007408 0.83 TMEM97 (0.56) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL28429220 0.83 USP19 (0.49) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL1088050 0.83 ALDH1A1 (0.48) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL3902852 0.82 SMN1; SMN2 (0.56) TMEM97SIGMAR1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075345-A1 Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II YANG JI CHEMICAL COMPANY LTD. (KR) 2005-04-07 US disclosed
EP-1456186-A1 NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A SB 2 /SB PHOSPHOLIPASE OF GROUP II Yang Ji Chemical Company Ltd. (KR) 2004-09-15 EP disclosed
WO-2003048139-A1 NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A2 PHOSPHOLIPASE OF GROUP II YANG JI CHEMICAL COMPANY LTD. (KR) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075345-A1 Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II AMY2A, PNLIP, IAPP ELANE 742/4885PLA2G2A 35/4885PRCP 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.